The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 2, 1999, Pages 392-399

  Hingorani, Melanie ^a,b   Calder, Virginia L ^b   Buckley, Roger J ^a   Lightman, Susan ^a,b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

ADULT; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; KERATOCONJUNCTIVITIS; LYMPHOCYTE COUNT; MALE; MAST CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TOPICAL DRUG ADMINISTRATION;

EID: 0032921399     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990;97:992-1000.
2. Tuft SJ, Kemeny MD, Dart JKG, Buckley RJ. Clinical features of atopic keratoconjunctivitis. Ophthalmology. 1991;98:150-158.
3. Akova YA, Rodriguez A, Foster CS. Atopic keratoconjunctivitis. Ocul Immunol Inflamm. 1994;2:125-144.
4. Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs. 1995;50:208-221.
5. Jaanus SD. Anti-inflammatory drugs. In: Bartletti JD, Jaanus SD, eds. Clinical Ocular Pharmacology. 2nd ed. Toronto: Butterworth; 1989:163-197.
6. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol. 1990;110:641-645.
7. Secchi AG, Tognon MS, Leonardi A. Topical cyclosporine A in the treatment of vernal and other immunologically mediated keratoconjunctivitis. In: Usui M, Ohno S, Aoki K, eds. Ocular Immunology Today. Amsterdam: Elsevier Science Publishers; 1990:37-42.
8. Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology. 1991;98:1679-1684.
9. BenEzra D, Pe'er J, Brodsky M, Cohen E. Cyclosporine eye drops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986;101:278-282.
10. BenEzra D, Matamoros N, Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc. 1988;20:644-649
11. BenEzra D. The role of cyclosporin eye drops in ocular inflammatory diseases. Ocul Immunol Inflamm. 1993;1:159-162.
12. Hingorani M, Moodaley L, Calder V, Buckley RJ, Lightman SL. The role of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105:1715-1720.
13. El-Asrar AM, Van den Oord JJ, Geboes K, Missotten L, Emrah MH, Desmet V. Immunopathological study of vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 1989;227:374-379.
14. Metz DP, Bacon AS, Holgate S, Lightman SL. Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease. J Allergy Clin Immunol. 1996;98:686-696.
15. Hingorani M, Lightman SL. Immunopathogenesis of atopic eye disease. Current Media Literature-Allergy. 1997;5:31-40.
16. Maggi E, Biswas P, DelPrete G, et al. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol. 1991;146:1169-1174.
17. Calder V, Hingorani M, Metz D, Lightman SL. T cell cytokine production in ocular allergic diseases. J Allergy Clin Immunol. 1998;100:817-822.
18. El-Asrar AMA, Tabbara KF, Geboes K, Missotten L, Desmet V. An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis. Am J Ophthalmol. 1996;121:156-161.
19. BenEzra D, Bonini S, Carreras B, et al. Guidelines on the diagnosis and treatment of conjunctivitis. Ocul Immunol Inflamm. 1994; 2(suppl):S17-S39.
20. Britten KM, Howarth PH, Roche W.R. Immunohistochemistry on resin sections, a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem. 1993;68:271-280.
21. Bernauer W, Wright P, Dart JKG, Leonard JN, Lightman S. Cytokines in the conjunctiva of acute and chronic mucous membrane pemphigoid: an immunohistochemical analysis. Graefes Arch Clin Exp Ophthalmol. 1993;231:563-570.
22. Koo J, Lee J. Cyclosporine, what clinicians need to know. Dermatol Clin. 1995;13:897-907.
23. Power WJ, Mullaney P, Farrell M, Collum LM. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjögren's syndrome. Cornea. 1993;12:507-511.
24. Holland EJ, Chan C, Kuwabara T, et al. Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol. 1989;107:160-166.
25. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory diseases. Cornea. 1993;12:413-419.
26. Liegener JT, Yee RW, Wild JH. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109:610-612.
27. Zierhut M, Thiel HJ, Weidle EG, et al. Topical treatment of severe corneal ulcers with cyclosporin A. Graefes Arch Clin Exp Ophthalmol. 1989;227:30-35.
28. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high risk corneal transplants. Ophthalmology. 1989;96: 1144-1150.
29. Kronke M, Leonard WJ, Depper JM, Arya SK, Wong Staal F, Gallo RC. Cyclosporin A inhibits T-cell growth factor, gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA. 1984; 81:5214-5218.
30. Borel JF, Baumann G, Chapman I, et al. In vivo pharmacological effects of ciclosporin and some analogues. Adv Pharmacol. 1996; 35:115-246.
31. Foxwell BM, Simon JJ, Herrero JJ, et al. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A. Immunology. 1990;69:104-109.
32. Haczku AF, Kay AB, Corrigan CJ. Inhibition of re-expression of surface CD4, but no CD8, on activated human T-lymphocytes by the immunosuppressive drugs dexamethasone and cyclosporine A: correlation with inhibition of proliferation. Int J Immunopharmacol. 1996;18:45-52.
33. Chan CC, Nussenblatt RB, Ni M, Shaozhen S, Mao W. Immunohistochemical markers in the normal human epibulbar conjunctiva from fetus to adult. Arch Ophthalmol. 1988;106:215-217.
34. Sacks EH, Wieczorek R, Jakobiec FA, Knowles DM. Lymphocyte subpopulations in the normal human conjunctiva: a monoclonal antibody study. Ophthalmology. 1986;93:1276-1283.
35. Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology. 1991;98:1190-1196.
36. Bernuaer W, Wright P, Dart JKG, Leonard JN, Lightman S. The conjunctiva in acute and chronic mucous membrane pemphigoid. Ophthalmology. 1993;100:339-346.
37. Bhan AK, Fujikawa LS, Foster CS. T cell subsets and Langerhans cells in normal and diseased conjunctiva. Am J Ophthalmol. 1982; 94:205-212.
38. Jakobiec FA, Lefkowitch J, Knowles DM. B- and T-lymphocytes in ocular disease. Ophthalmology. 1984;91:635-654.
39. Jones DT, Monroy D, Ji Z, Atherton SS, Pflugfelder SC. Sjögrens syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. Invest Ophthalmol Vis Sci. 1994;35: 3493-3504.
40. Badouin C, Haouat N, Brignole F, Bayle J, Gastaud P. Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens. Br J Ophthalmol. 1992;76:545-549.
41. Buurman WA, Groenewegen G, Van der Linden CJ, Kootstra G. MHC class II expression and cyclosporine. Transplant Proc. 1986; 18:855-857.
42. Whistler RI, Lindsey JA, Proctor KVW, Newhouse YG, Cornwell DG. The impaired ability of human monocytes to stimulate autologous and allogeneic mixed lymphocyte reactions after exposure to cyclosporine. Transplantation. 1985;40:57-65.
43. Groenewegen G, Buurman WA, Jeunhomme GMAA, Van der Linden CJ. Effect of cyclosporine on MHC class II antigen expression on arterial and venous endothelium in vitro. Transplantation. 1985;40:21-25.
44. Reem GH, Cook LA, Vilcek J. Gamma-interferon synthesis by human thymocytes and T lymphocytes is inhibited by cyclosporin A. Science. 1983;221:63-65.
45. Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol. 1986; 136:1315-1321.
46. Volk HD, Waschke SR, Diezel W, Grohow R, von Baehr R, Fiebig H. Decrease of HLA-DR antigen expression by human monocytes during cultivation in absence of exogenous or endogenous interferon-gamma. Immunol Lett. 1985;10:103-107.
47. Abu El-Asrar AM, Van den Oord JJ, Billau A, Desmet V, Emarah MH, Missotten L. Recombinant interferon-gamma induces HLA-DR expression on human corneal epithelial and endothelial cells in vitro: a preliminary report. Br J Ophthalmol. 1989;73:587-590.
48. Lun MT, Cochi S, Floravanti D, et al. Effect of cyclosporin A on B cell maturation and differentiation. Drugs Exp Clin Res. 1991;17: 493-500.
49. Punnonen J, Eskola J. Recombinant interleukin-2 induces proliferation and differentiation of human B lymphocytes. Acta Pathol Microbiol Immunol Scand. 1987;95:167-172.
50. Boyd AW, Tedder TF, Griffin JD. Pre-exposure of resting B cells to interferon-γ enhances their proliferative response to subsequent activation signals. Cell Immunol. 1987;106:355-363.
51. Thomson AW. The effects of cyclosporin A on non-T cell components of the immune system. J Autoimmun. 1992;5(suppl):167-176.
52. Mongini PK, Blessinger CA, Dalton JP, Seki T. Differential effects of cyclosporin A on diverse B cell activation phenomena triggered by cross-linking of membrane IgM. Cell Immunol. 1992;140:478-494.
53. Del Prete GF, Maggi E, Parronchi P, et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol. 1988;140:4193-4198.
54. Bonini S. IgE and non-IgE mechanisms in ocular allergy. Ann Allergy. 1993;71:296-299.
55. Okudaira H, Sakurai Y, Terada K, Terada E, Ogita T, Miyamoto T. Cyclosporin A-induced suppression of ongoing IgE antibody formation in the mouse. Int Arch Allergy Appl Immunol. 1986;79: 164-168.
56. Munro CS, Higgins EM, Marks JM, Daly BM, Friedmann PS, Shuster S. Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reaction. Br J Dermatol. 1991; 124:43-48.
57. Mozzanica N, Pigatto PD, Finzi AF. Cyclosporin in psoriasis: pathophysiology and experimental data. Dermatology. 1993; 187(suppl):3-7.
58. Norris AA, Jackson DM, Eady RP. Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs. Clin Exp Immunol. 1992;89:347-350.
59. Elwood W, Lotvall JO, Barnes PJ, Chung FC. Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. Am Rev Respir Dis. 1992;145:1289-1294.
60. Wershil BK, Furuta GT, Lavigne JA, Choudhury AR, Wang Z-S, Galli SJ. Dexamethasone or cyclosporin A suppress mast cell-leukocyte cytokine cascades. J Immunol. 1995;154:1391-1398.
61. Hultsch T, Rodriguez JL, Kaliner MA, et al. Cyclosporin A inhibits degranulation of rat basophilic leukaemia cells and human basophils: inhibition of mediator release without affecting PI hydrolysis or calcium fluxes. J Immunol. 1990;144:2659-2664.
62. Triggiani M, Cirillo R, Lichtenstein LM, et al. Inhibition of histamine and prostaglandin D2 release from human lung mast cells by cyclosporin A. Intern Arch Allergy Appl Immunol. 1989;88:253-255.
63. Kita H, Ohnishi T, Okubu Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/monocyte colony-stimulating factor and interleukin-3 release from human peripheral blood eosinophils and neutrophils. J Exp Med. 1991;174:745-748.
64. Cirilo R, Triggianai M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from human basophils, presumably by interacting with cyclophilin. J Immunol. 1990;144:3891-3897.